Clinical Trial Update: The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of afatinib in lung cancer (ATTAIN) has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-04-30